Equities research analysts expect Uniqure NV (NASDAQ:QURE) to post sales of $2.91 million for the current quarter, Zacks reports. Four analysts have made estimates for Uniqure’s earnings, with the highest sales estimate coming in at $3.50 million and the lowest estimate coming in at $2.00 million. Uniqure posted sales of $2.58 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 12.8%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, March 13th.

According to Zacks, analysts expect that Uniqure will report full-year sales of $12.69 million for the current financial year, with estimates ranging from $11.70 million to $13.18 million. For the next fiscal year, analysts forecast that the company will report sales of $11.68 million, with estimates ranging from $8.00 million to $14.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Uniqure.

Uniqure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.03. The company had revenue of $3.15 million during the quarter, compared to analyst estimates of $3.37 million. Uniqure had a negative return on equity of 58.49% and a negative net margin of 725.04%.

Several equities research analysts recently issued reports on QURE shares. Janney Montgomery Scott reissued a “buy” rating on shares of Uniqure in a research note on Wednesday, August 8th. Cowen reissued a “buy” rating on shares of Uniqure in a research note on Monday, August 13th. Cantor Fitzgerald started coverage on Uniqure in a research note on Thursday, July 26th. They set an “overweight” rating and a $58.00 price objective for the company. Zacks Investment Research raised Uniqure from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Wednesday, October 10th. Finally, HC Wainwright set a $48.00 price objective on Uniqure and gave the company a “buy” rating in a research note on Wednesday, November 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $49.67.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. California Public Employees Retirement System purchased a new stake in Uniqure during the first quarter valued at about $332,000. Atria Investments LLC purchased a new stake in Uniqure during the second quarter valued at about $247,000. Fred Alger Management Inc. purchased a new stake in Uniqure during the second quarter valued at about $983,000. Eqis Capital Management Inc. purchased a new stake in Uniqure during the second quarter valued at about $3,003,000. Finally, Bank of New York Mellon Corp purchased a new stake in Uniqure during the second quarter valued at about $628,000. Institutional investors and hedge funds own 59.10% of the company’s stock.

NASDAQ:QURE opened at $23.93 on Wednesday. The firm has a market cap of $958.81 million, a P/E ratio of -8.14 and a beta of 0.78. Uniqure has a 52-week low of $13.71 and a 52-week high of $43.23. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.56 and a quick ratio of 7.56.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Recommended Story: How to use beta for portfolio diversification

Get a free copy of the Zacks research report on Uniqure (QURE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.